FH001

FH001 is an orally bioavailable small molecule inhibitor of the voltage-gated sodium channel Nav1.8 (encoded by the SCN10A gene), currently in clinical development by Hengji Medicine (Shanghai) and XuanTai Pharmaceutical. Nav1.8 is a key mediator of action potential propagation in peripheral nociceptive neurons, and its selective inhibition is a validated strategy for treating pain without the central nervous system side effects (such as sedation or addiction) associated with opioids or the cardiovascular risks of NSAIDs. FH001 is being evaluated in Phase 2 clinical trials for the management of acute pain (e.g., post-operative pain) and chronic neuropathic pain, specifically diabetic peripheral neuropathic pain (DPNP).